Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous TILs and IL-2 in Solid Tumors
NCT03991741Phase 1Terminated
- Start
- Oct 2020
- Primary completion
- Jan 2023
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MDA-TIL in melanoma and head and neck squamous cell carcinoma (HNSCC). Primary endpoint: Dose Limiting Toxicity at 2 months. Started Oct 2020; status: terminated.
02
Drugs
MDA-TIL
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03991741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991741.